Previous 10 | Next 10 |
NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will announce its first-quarter 2022 financial results by posting them on the IR...
Are you looking for penny stocks to buy now ? You’re not alone, and some traders push Reddit stocks aside for something else. They’re putting together their list of penny stocks based on “following” the money. This strategy is simple, has plenty of specul...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Investment banks are continuing to release positive coverage for psychedelic stocks and the latest report from Roth Capital is no exception. On April 19, Roth Capita...
NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conference in April: ...
Atai Life Sciences (NASDAQ:ATAI) stock gained 4.9% Wednesday days after the firm disclosed insider buying of shares worth ~$540K. 10% owner Apeiron Investment bought 111.6K shares at $4.70-4.90. Apeiron now holds ~1.3M shares in ATAI. ATAI's ownership structure: ATAI stock has declined 3...
NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: PolarityTE, Inc. (NASDAQ: PTE), Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), atai Life Sciences N....
Most people in the psychedelics industry believe that the growing superstar of psychedelic medicines is psilocybin—the “psychedelic du jour” as one scientist put it to Psychedelia . But ketamine is quickly changing that perception. Ke...
atai Life Sciences N.V. (ATAI) Q4 2021 Results Earnings Conference Call March 30, 2022, 08:30 AM ET Company Participants Colin Keeler - Manager, Corporate Finance Christian Angermayer - Founder and Chairman Florian Brand - Co-Founder, Chief Executive Officer and Managing Director Srinivas Rao...
ATAI Life Sciences press release (NASDAQ:ATAI): FY GAAP EPS of -$1.21 misses by $0.44. Revenue of $20.37M beats by $3.13M. For further details see: ATAI Life Sciences GAAP EPS of -$1.21 misses by $0.44, revenue of $20.37M beats by $3.13M
– Highlights included positive Phase 2b data with COMP360 from a ground-breaking treatment resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in cognitive impairment associated with schizophrenia (CIAS), clinical trial initia...
News, Short Squeeze, Breakout and More Instantly...
ATAI Life Sciences N.V. Company Name:
ATAI Stock Symbol:
NASDAQ Market:
ATAI Life Sciences N.V. Website:
Psychedelics such as DMT, LSD and psilocybin have demonstrated promise in the treatment of affective symptoms of a range of disorders. These drugs work by inducing an altered state of consciousness , which includes intensified perceptions and emotions, which have been associated with therapeutic...